1-2 of 2
Kenji Tanaka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Hiroki Irie, Kimihiro Ito, Yayoi Fujioka, Kei Oguchi, Akio Fujioka, Akihiro Hashimoto, Hirokazu Ohsawa, Kenji Tanaka, Kaoru Funabashi, Hikari Araki, Yuichi Kawai, Tadashi Shimamura, Renu Wadhwa, Shuichi Ohkubo, Kenichi Matsuo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (4): 733–742.
https://doi.org/10.1158/1535-7163.MCT-18-1085
Published: 01 April 2019
View article titled, TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Open the PDF for TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations

Shinichi Hasako, Miki Terasaka, Naomi Abe, Takao Uno, Hirokazu Ohsawa, Akihiro Hashimoto, Ryoto Fujita, Kenji Tanaka, Takashige Okayama, Renu Wadhwa, Kazutaka Miyadera, Yoshimi Aoyagi, Kazuhiko Yonekura, Kenichi Matsuo
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (8): 1648–1658.
https://doi.org/10.1158/1535-7163.MCT-17-1206
Published: 31 July 2018
View article titled, TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Open the PDF for TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations in another window
Includes: Supplementary data